Maxcyte Signs $125M M&A Deal with Akron BioProducts LLC
MaxCyte has entered into a definitive agreement to acquire Akron BioProducts LLC for $105 million in cash, $20 million in deferred cash payments, and approximately 20.6 million shares of common stock. The acquisition of the GMP-grade reagent supplier is expected to nearly double MaxCyte's revenue and expand its cell therapy manufacturing offerings. The deal is expected to close before the end of 2026, subject to regulatory approvals.
- Value
- $125M
- Counterparty
- Akron BioProducts LLC
“Today, we announced our intention to acquire Akron Bio, a transformational moment for MaxCyte. I believe combining MaxCyte and Akron will expand our commercial opportunity, strengthen our financial profile, and drive long-term value.”
Maher Masoud, President and CEO of MaxCyte